BMI View: Despite the small size of the Singaporean pharmaceutical market, the country’s consistent drive
into R&D, strong government commitment towards healthcare provision and its ageing population continue
to present significant commercial opportunities for pharmaceutical firms. Furthermore, per capita
pharmaceutical spending is high relative to the region which will be a strong plus for innovative
drugmakers.
Headline Expenditure Projections
? Pharmaceuticals: SGD1.04bn (USD822mn) in 2014 to SGD1.1bn (USD788mn) by 2015; +5.4% in
local currency terms and -4.1% in USD terms. Forecast maintained from previous quarter.
? Healthcare: SGD18.27bn (USD14.42bn) in 2014 to SGD19.67bn (USD14.13bn) by 2015; +7.7% in
local currency terms and -2.0% in USD terms. Forecast maintained from previous quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Singapore 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Singapore 2011-2019) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2011-2019) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2011-2019) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2011-2019) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Singapore 2011-2019) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Singapore 2011-2019) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Singapore 2011-2019) 22
OTC Medicine Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Singapore 2011-2019) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Singapore 2013-2019) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Singapore 2013-2019) 27
Industry Risk/Reward Index 28
Asia Pacific Risk/Reward Index 28
Singapore Risk/Reward Index 35
Rewards 35
Risks 35
Regulatory Review 36
Table: Regulatory Process Time Taken Under The CECA And Under The Abridged GDA 38
Regional Harmonisation 38
Intellectual Property Issues 40
Trade Agreements 41
Pricing And Reimbursement Regime 42
Market Overview 45
Healthcare Sector 45
Table: Health Funding Sources In Singapore (SGDmn) 50
Healthcare Insurance 50
Table: Healthcare Resources (Singapore 2009-2014) 54
Table: Healthcare Activity (Singapore 2009-2014) 54
Table: Healthcare Personnel (Singapore 2009-2014) 54
Research & Development 55
Clinical Trials 57
Epidemiology 58
Table: Estimated Number Of New Cases Of Cancer In Singapore 59
Competitive Landscape 62
Research-Based Industry 62
Table: Multinational Pharmaceutical Firm Presence In Singapore 62
Table: Multinational Market Activity 63
Table: Leading Generic Drugmakers In Singapore 65
Pharmaceutical Distribution 66
Pharmaceutical Retail Sector 69
Company Profile 71
Baxter 71
GlaxoSmithKline 73
Haw Par 76
Merck & Co 78
MerLion 81
Novartis 84
Pfizer 87
Sanofi 90
Sci Gen 92
Demographic Forecast 95
Demographic Outlook 95
Table: Population Headline Indicators (Singapore 1990-2025) 96
Table: Key Population Ratios (Singapore 1990-2025) 96
Table: Urban/Rural Population & Life Expectancy (Singapore 1990-2025) 97
Table: Population By Age Group (Singapore 1990-2025) 97
Table: Population By Age Group % (Singapore 1990-2025) 98
Glossary 100
Methodology 102
Pharmaceutical Expenditure Forecast Model 102
Healthcare Expenditure Forecast Model 102
Notes On Methodology 103
Risk/Reward Index Methodology 104
Index Overview 105
Table: Pharmaceutical Risk/Reward Index Indicators 105
Indicator Weightings 106

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Singapore 2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Singapore 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2011-2019)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Singapore 2011-2019)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Singapore 2011-2019)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Singapore 2011-2019)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Singapore 2011-2019)
Table: Pharmaceutical Trade Data And Forecasts (Singapore 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Singapore 2013-2019)
Table: Regulatory Process Time Taken Under The CECA And Under The Abridged GDA
Table: Health Funding Sources In Singapore (SGDmn)
Table: Healthcare Resources (Singapore 2009-2014)
Table: Healthcare Activity (Singapore 2009-2014)
Table: Healthcare Personnel (Singapore 2009-2014)
Table: Estimated Number Of New Cases Of Cancer In Singapore
Table: Multinational Pharmaceutical Firm Presence In Singapore
Table: Multinational Market Activity
Table: Leading Generic Drugmakers In Singapore
Table: Population Headline Indicators (Singapore 1990-2025)
Table: Key Population Ratios (Singapore 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Singapore 1990-2025)
Table: Population By Age Group (Singapore 1990-2025)
Table: Population By Age Group % (Singapore 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators